Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations

Trial Profile

A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary) ; Capecitabine; Eribulin; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OlympiAD
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Nov 2019 Results assessing commonly reported CTCAE grade ≥3 AE probabilities extracted from the publications of two Phase III RCTs, OlympiAD and EMBRACA studies,presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 22 Aug 2019 Results assessing effects of olaparib on health-related quality of life published in the European Journal of Cancer.
    • 31 May 2019 Results comparing efficacy and safety of olaparib and talazoparib in patients with metastatic breast cancer, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top